Atezolizumab
- Generic Name
- Atezolizumab
- Brand Names
- Tecentriq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1380723-44-3
- Unique Ingredient Identifier
- 52CMI0WC3Y
- Background
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.
- Indication
Atezolizumab has approved indications for the following conditions:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Alveolar Soft Part Sarcoma (ASPS)
- Associated Conditions
- Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
- Associated Therapies
- -
A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)
- Conditions
- Interventions
- First Posted Date
- 2021-06-21
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 29
- Registration Number
- NCT04933227
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, China
🇨🇳Jilin Cancer Hospital, Changchun, China
🇨🇳Beijing Cancer Hospital, Beijing, China
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 176
- Registration Number
- NCT04931342
- Locations
- 🇫🇷
CHU Besançon - Hôpital Jean Minjoz, Besançon Cedex, France
🇫🇷Institut Bergonie; Oncologie, Bordeaux, France
🇫🇷Centre Francois Baclesse; Oncologie, Caen, France
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 542
- Registration Number
- NCT04929223
- Locations
- 🇺🇸
cCare, Encinitas, California, United States
🇺🇸Los Angeles Cancer Network, Los Angeles, California, United States
🇺🇸Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
Liver Directed RT + Chemo-immunotherapy for ES-SCLC
- Conditions
- Interventions
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Brian Henick, MD
- Target Recruit Count
- 18
- Registration Number
- NCT04923776
- Locations
- 🇺🇸
Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, New York, New York, United States
Temozolomide and Atezolizumab as Second or Third Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- Dwight Owen
- Target Recruit Count
- 56
- Registration Number
- NCT04919382
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
🇺🇸University of Illinois Cancer Center, Chicago, Illinois, United States
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
- Conditions
- Clinical Stage IV Merkel Cell Carcinoma AJCC v8Advanced Bladder CarcinomaClinical Stage III Cutaneous Melanoma AJCC v8Pathologic Stage IIIA Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8Stage III Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IV Bladder Cancer AJCC v8Stage IV Lung Cancer AJCC v8Advanced Lung Non-Small Cell Carcinoma
- Interventions
- First Posted Date
- 2021-05-26
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT04902040
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-05-21
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Xilio Development, Inc.
- Target Recruit Count
- 136
- Registration Number
- NCT04896697
- Locations
- 🇺🇸
Mayo Clinic Hospital, Rochester, Minnesota, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸City of Hope-Lennar, Irvine, California, United States
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
- Conditions
- Interventions
- First Posted Date
- 2021-05-05
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1150
- Registration Number
- NCT04873362
- Locations
- 🇺🇸
Alabama Oncology, Alabaster, Alabama, United States
🇺🇸Roy and Patricia Disney Family Cancer Center- Providence Saint Joseph Medical Center, Burbank, California, United States
🇺🇸Innovation Clinical Research Institute, Cerritos, California, United States
Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancer
- Conditions
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- I-Mab Biopharma US Limited
- Registration Number
- NCT04869501
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸Arizona Oncology Associates, P.C., Tucson, Arizona, United States
A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 80
- Registration Number
- NCT04857138
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
🇬🇧Western General Hospital; Edinburgh Cancer Center, Edinburgh, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.